Cargando…

Brain Metastases among Cancer Patients Diagnosed from 2010–2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence

The incidence of BM among Canadian cancer patients is unknown. We aimed to estimate IP of BM at the time of cancer diagnosis and during the lifetime of patients with selected primary cancers. Data on BM at diagnosis from 2010–2017 was obtained from the CCR. Site-specific IPs of BM were estimated fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiaqi L., Walker, Emily V., Paudel, Yuba Raj, Davis, Faith G., Yuan, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946963/
https://www.ncbi.nlm.nih.gov/pubmed/35323369
http://dx.doi.org/10.3390/curroncol29030169
_version_ 1784674323346227200
author Liu, Jiaqi L.
Walker, Emily V.
Paudel, Yuba Raj
Davis, Faith G.
Yuan, Yan
author_facet Liu, Jiaqi L.
Walker, Emily V.
Paudel, Yuba Raj
Davis, Faith G.
Yuan, Yan
author_sort Liu, Jiaqi L.
collection PubMed
description The incidence of BM among Canadian cancer patients is unknown. We aimed to estimate IP of BM at the time of cancer diagnosis and during the lifetime of patients with selected primary cancers. Data on BM at diagnosis from 2010–2017 was obtained from the CCR. Site-specific IPs of BM were estimated from provincial registries containing ≥90% complete data on BM. The CCR IP estimates and the IP estimates from literature were applied to the total diagnosed primary cancers to estimate the number of concurrent BM and lifetime BM from 2010–2017 in Canada, respectively. The annual average number of patients with BM at diagnosis from all cancer sites was approximately 3227. The site-specific IPs of BM at diagnosis were: lung (9.42%; 95% CI: 9.16–9.68%), esophageal (1.58%; 95% CI: 1.15–2.02%), kidney/renal pelvis (1.33%; 95% CI: 1.12–1.54%), skin melanoma (0.73%; 95% CI: 0.61–0.84%), colorectal (0.22%; 95% CI: 0.18–0.26%), and breast (0.21%; 95% CI: 0.17–0.24%). Approximately 76,546 lifetime BM cases (or 5.70% of selected fifteen primary cancers sites) were estimated to have occurred from the 2010–2017 cancer patient cohort. These findings reflect results of population analyses in the US and Denmark. We recommend improved standardization of the collection of BM data within the CCR.
format Online
Article
Text
id pubmed-8946963
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89469632022-03-25 Brain Metastases among Cancer Patients Diagnosed from 2010–2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence Liu, Jiaqi L. Walker, Emily V. Paudel, Yuba Raj Davis, Faith G. Yuan, Yan Curr Oncol Article The incidence of BM among Canadian cancer patients is unknown. We aimed to estimate IP of BM at the time of cancer diagnosis and during the lifetime of patients with selected primary cancers. Data on BM at diagnosis from 2010–2017 was obtained from the CCR. Site-specific IPs of BM were estimated from provincial registries containing ≥90% complete data on BM. The CCR IP estimates and the IP estimates from literature were applied to the total diagnosed primary cancers to estimate the number of concurrent BM and lifetime BM from 2010–2017 in Canada, respectively. The annual average number of patients with BM at diagnosis from all cancer sites was approximately 3227. The site-specific IPs of BM at diagnosis were: lung (9.42%; 95% CI: 9.16–9.68%), esophageal (1.58%; 95% CI: 1.15–2.02%), kidney/renal pelvis (1.33%; 95% CI: 1.12–1.54%), skin melanoma (0.73%; 95% CI: 0.61–0.84%), colorectal (0.22%; 95% CI: 0.18–0.26%), and breast (0.21%; 95% CI: 0.17–0.24%). Approximately 76,546 lifetime BM cases (or 5.70% of selected fifteen primary cancers sites) were estimated to have occurred from the 2010–2017 cancer patient cohort. These findings reflect results of population analyses in the US and Denmark. We recommend improved standardization of the collection of BM data within the CCR. MDPI 2022-03-18 /pmc/articles/PMC8946963/ /pubmed/35323369 http://dx.doi.org/10.3390/curroncol29030169 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Jiaqi L.
Walker, Emily V.
Paudel, Yuba Raj
Davis, Faith G.
Yuan, Yan
Brain Metastases among Cancer Patients Diagnosed from 2010–2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence
title Brain Metastases among Cancer Patients Diagnosed from 2010–2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence
title_full Brain Metastases among Cancer Patients Diagnosed from 2010–2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence
title_fullStr Brain Metastases among Cancer Patients Diagnosed from 2010–2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence
title_full_unstemmed Brain Metastases among Cancer Patients Diagnosed from 2010–2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence
title_short Brain Metastases among Cancer Patients Diagnosed from 2010–2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence
title_sort brain metastases among cancer patients diagnosed from 2010–2017 in canada: incidence proportion at diagnosis and estimated lifetime incidence
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946963/
https://www.ncbi.nlm.nih.gov/pubmed/35323369
http://dx.doi.org/10.3390/curroncol29030169
work_keys_str_mv AT liujiaqil brainmetastasesamongcancerpatientsdiagnosedfrom20102017incanadaincidenceproportionatdiagnosisandestimatedlifetimeincidence
AT walkeremilyv brainmetastasesamongcancerpatientsdiagnosedfrom20102017incanadaincidenceproportionatdiagnosisandestimatedlifetimeincidence
AT paudelyubaraj brainmetastasesamongcancerpatientsdiagnosedfrom20102017incanadaincidenceproportionatdiagnosisandestimatedlifetimeincidence
AT davisfaithg brainmetastasesamongcancerpatientsdiagnosedfrom20102017incanadaincidenceproportionatdiagnosisandestimatedlifetimeincidence
AT yuanyan brainmetastasesamongcancerpatientsdiagnosedfrom20102017incanadaincidenceproportionatdiagnosisandestimatedlifetimeincidence